Category: AMT-130
Shots: The DSMB recommended the P-I/II clinical trial of AMT-130 in patients with Huntington’s disease, after reviewing safety data from the four patients in the higher-dose cohort In Aug’21, the company has completed enrollment in the second, higher-dose cohort in the P-I/II clinical trial of AMT-130 in 14 patients out of which eight patients received […]
Shots: The DSMB recommended continued the dosing in the P- I/II clinical trial assessing AMT-130 in patients with a second higher-dose cohort, after review safety data from the first cohort of ten patients The first cohort of P- I/II trial for AMT-130 in 10 patients out of which six patients received treatment with AMT-130 and […]
Shots: The company has completed the enrollment in the first cohort of P- I/II trial involves assessing AMT-130 in 10 patients, out of which six patients received treatment with AMT-130 and four patients received imitation surgery for early manifest HD The company plans to initiate a second clinical study of AMT-130 in the EU in […]